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Summary
 
We demonstrated previously that a single injection of recombinant human macrophage colony-
stimulating factor (rhM-CSF) is sufficient for osteoclast recruitment and survival in osteopetrotic
(
 
op/op
 
) mice with a deficiency in osteoclasts resulting from a mutation in M-CSF gene. In this
study, we show that a single injection of recombinant human vascular endothelial growth factor
(rhVEGF) can similarly induce osteoclast recruitment in
 
 op/op
 
 mice. Osteoclasts predominantly
expressed VEGF receptor 1 (VEGFR-1), and activity of recombinant human placenta growth
factor 1 on osteoclast recruitment was comparable to that of rhVEGF, showing that the VEGF
signal is mediated through VEGFR-1. The rhM-CSF–induced osteoclasts died after injections of
VEGFR-1/Fc chimeric protein, and its effect was abrogated by concomitant injections of
rhM-CSF. Osteoclasts supported by rhM-CSF or endogenous VEGF showed no significant dif-
ference in the bone-resorbing activity. 
 
op/op
 
 mice undergo an age-related resolution of osteo-
petrosis accompanied by an increase in osteoclast number. Most of the osteoclasts disappeared
after injections of anti-VEGF antibody, demonstrating that endogenously produced VEGF is re-
sponsible for the appearance of osteoclasts in the mutant mice. In addition, rhVEGF replaced
rhM-CSF in the support of in vitro osteoclast differentiation. These results demonstrate that
M-CSF and VEGF have overlapping functions in the support of osteoclastic bone resorption.
Key words: osteoclasts • vascular endothelial growth factor • vascular endothelial growth 
factor receptor • macrophage colony-stimulating factor • osteopetrosis
 
M
 
ice homozygous for the recessive mutation, osteopetro-
sis (
 
op
 
), on chromosome 3 have a severe deficiency of
osteoclasts, monocytes, and macrophages in various organs
(1–3). The deficiency is caused by the absence of functional
macrophage colony-stimulating factor (M-CSF or CSF-1) as a
result of a single basepair insertion within the coding region of
the M-CSF gene (4) and can be cured by injections of recom-
binant human (rh)M-CSF (5–8). Direct action of M-CSF on
osteoclast lineage cells is demonstrated by the expression of the
receptor for M-CSF, c-Fms, in osteoclasts both in vitro (9)
and in vivo (10). These findings indicate that M-CSF plays an
essential role in the differentiation of osteoclasts, as well as
macrophages in some organs, under physiological conditions.
However, severe osteopetrosis in 
 
op
 
/
 
op
 
 mice is evident only
during their youth and is progressively corrected in association
with an increase of osteoclasts (1, 2, 11). We found that when
injected at high doses (
 
.
 
5 
 
m
 
g/mouse), only a single injec-
tion of rhM-CSF is sufficient to induce a synchronous
wave of osteoclast recruitment, survival, and active bone re-
sorption for a prolonged period in 
 
op
 
/
 
op
 
 mice (12, 13).
These  observations have suggested the presence of other regu-
latory factor(s) that are responsible for osteoclastic bone re-
sorption in the absence of M-CSF. In this context, controver-
sial data have been reported on the effects of GM-CSF on the
cure of osteopetrosis in 
 
op
 
/
 
op
 
 mice, whereas several in vitro
studies have suggested a role of this cytokine in osteoclast
differentiation (14–16). Wiktor-Jedrzejczak et al. (17) and
Nilsson et al. (18) reported that GM-CSF can correct mac-
rophage deficiencies but fails to resolve osteopetrosis. Very re-
cently, Myint et al. (19) reported that GM-CSF and/or IL-3
 
at low doses can induce osteoclast development in 
 
op
 
/
 
op
 
 mice.
c-Fms is one of the eight members of the platelet-
derived growth factor receptor (PDGFR) family (20). As spe-
cific receptors for vascular endothelial growth factor (VEGF),
two receptor tyrosine kinases of the PDGFR family,
VEGFR-1/Flt-1 and VEGFR-2/KDR/Flk-1, as well as 
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neuropilin-1, have been identified (21). In contrast to en-
dothelial cells which express all of the VEGFRs, monocyte/
macrophage lineage cells predominantly express VEGFR-1
(21–23). VEGFR-1 mediates chemotactic response of the
cells to VEGF or placenta growth factor 1 (PlGF-1), which
shows high homology to VEGF and is expressed in umbili-
cal vein endothelia and placenta (21–26).
Taking note of the close lineage relationship between mac-
rophages and osteoclasts, we show in this study that VEGF
can fully compensate for the deficiency of M-CSF in 
 
op
 
/
 
op
 
mice in osteoclastic bone resorption, manifesting a unique
type of redundancy in cytokine signaling by using different
ligand–receptor combinations. Furthermore, we present evi-
dence that endogenously produced VEGF is responsible for
the age-related resolution of osteopetrosis in 
 
op
 
/
 
op
 
 mice.
 
Materials and Methods
 
Mice. op
 
/
 
op
 
 mice and their normal littermates (
 
1
 
/?) were
raised in our animal facility as described previously (6, 12). Mice
of 
 
op/op
 
 genotype were identified at 11 d of age by the absence of
incisor eruption. Male ddY mice were obtained from Saitama
Experimental Animals Supply (Sugito, Saitama, Japan).
 
Injection of Cytokines, Antibody, and/or VEGFR-1/Fc Chimeric
Protein into op/op Mice.
 
5 
 
m
 
g of either rhM-CSF (Austral Biologi-
cals), rhVEGF165 (Genzyme Corp.), rhVEGF121 (Genzyme
Corp.), or rhPlGF-1 (R&D Systems) was intraperitoneally in-
jected into 12-d-old 
 
op
 
/
 
op
 
 mice, and the mice were killed 3 or 7 d
after the injection. AFS98 rat anti–mouse c-Fms mAb (27) was
intraperitoneally injected at a dosage of 750 
 
m
 
g/mouse into mu-
tant mice both 2 h before and 24 h after the cytokine injection,
and the mice were killed 3 d after cytokine injection.
In another series of experiments, 
 
op/op
 
 mice were pretreated with
a single injection of rhM-CSF at 12 d of age. Starting at 4 d after the
pretreatment, 5 
 
m
 
g of either VEGFR-1/Fc chimeric protein (R&D
Systems) and/or rhM-CSF was intraperitoneally injected six times at
12-h intervals. The mice were killed 7 d after the pretreatment.
As a control for the chimeric protein, human IgG1 (ICN Pharma-
ceuticals) was injected similarly as above. rhM-CSF alone or together
with VEGFR-1/Fc was also consecutively injected six times at 12-h
intervals into the mutant mice starting at 12 d of age without pre-
treatment. Mice were killed 3 d after the onset of the treatment.
Five consecutive injections of 100 
 
m
 
g of goat anti–mouse
VEGF polyclonal antibody (R&D Systems) at 12-h intervals were
given to 2-mo-old 
 
op/op
 
 mice. As a control, goat IgG (Santa
Cruz Biotechnology) was injected similarly as above. The last
group of mice received a single dose of 5 
 
m
 
g rhVEGF165. All of
these mice were killed 3 d after the onset of the treatments.
 
Histological Observations. op/op
 
 mice were anesthetized with
ether and perfused with 4% periodate-lysine-paraformaldehyde
fixative solution (pH 7.4) through descending aorta. Femurs were
decalcified in 10% EDTA (pH 7.0) for 4 d and embedded in
paraffin. Longitudinal sections (7 
 
m
 
m thick) of the median por-
tion of whole femurs were stained for tartrate-resistant acid
phosphatase (TRAP) activity as described previously (12, 13) and
counterstained with hematoxylin. TRAP-positive cells with two
or more nuclei were counted as osteoclasts. Some sections were
stained by Mallory’s azan staining.
 
Immunohistochemical Staining for VEGFRs.
 
Femurs of 2–3-wk-old
 
1
 
/? or 
 
op/op
 
 mice were fixed and embedded in paraffin as de-
scribed above. Sections (5 
 
m
 
m thick) of the femurs were immu-
nohistochemically stained with rabbit anti–mouse VEGFR-1
 
polyclonal antibody (Santa Cruz Biotechnology) or AVAS12 rat
anti–mouse VEGFR-2 mAb (28), using Vectastain Elite ABC kits
(Vector Laboratories), and counterstained with hematoxylin. Nor-
mal rabbit IgG (Santa Cruz Biotechnology) and rat IgG2a (Santa
Cruz Biotechnology) were used as controls for the polyclonal and
monoclonal antibodies, respectively.
 
In Vitro Generation of Osteoclasts.
 
rhVEGF165 and rhM-CSF
were dissolved in fetal bovine serum (FBS) at concentrations of
2 
 
m
 
g/ml and 400 ng/ml, respectively. Wells of 96-well plates were
coated with 5 
 
m
 
l of either of the cytokine solutions or FBS and air
dried for 30 min. Bone marrow cells obtained from tibias and fe-
murs of 5–8-wk-old male ddY mice were passed through a Sepha-
dex G-10 (Amersham Pharmacia Biotech) column as described by
Ly and Mishell (29). Nonadherent cells were plated at a density of
10
 
5
 
 cells/well into the cytokine-coated wells and cultured with
 
a
 
-MEM supplemented with 15% FBS in the absence or presence
of 100 ng/ml of recombinant human receptor activator of nuclear
factor 
 
k
 
B ligand (rhRANKL; PeproTech) for 7 d. The final con-
centrations of rhVEGF165 and rhM-CSF were 100 and 20 ng/ml,
respectively. The cultures were fixed with 4% paraformaldehyde
and stained for TRAP as described above. The nonadherent bone
marrow cells were also inoculated onto dentine slices with a diam-
eter of 5 mm, placed in the wells of 24-well plates, similarly as de-
scribed above, and cultured for 7 d. The slices were examined by
backscattered electron microscopy as described previously (30).
 
Results and Discussion
 
To examine whether VEGF can compensate for the ab-
sence of functional M-CSF in 
 
op/op
 
 mice in the support of
osteoclast recruitment, we first injected either rhM-CSF,
rhVEGF165, rhVEGF121, or rhPlGF-1 into 12-d-old 
 
op/op
 
mice. As shown in Table I, a single 5-
 
m
 
g injection of any
of these factors was sufficient for the osteoclast recruitment
in the mutant mice, although the number of osteoclasts re-
cruited by rhVEGFs or rhPlGF-1 was 60–70% of that by
rhM-CSF. The antagonistic anti–c-Fms mAb, AFS98 (27),
decreased osteoclast recruitment by rhM-CSF to 
 
z
 
25%,
but not that by rhVEGFs or rhPlGF-1, confirming that
c-Fms mediates the response of osteoclast precursor cells to
M-CSF, but not the response to VEGFs or PlGF-1.
As shown in Fig. 1 A, osteoclasts were strongly stained
with rabbit anti–mouse VEGFR-1 polyclonal antibody,
whereas endothelial cells were weakly positive for VEGFR-1.
In contrast, osteoclasts were not stained with AVAS12
anti–mouse VEGFR-2 mAb (28), while endothelial cells
were positively stained for VEGFR-2 (Fig. 1 B). Neither
normal rabbit IgG (Fig. 1 C) nor rat IgG2a (data not
shown) stained any cell types. rhM-CSF–induced osteo-
clasts in 
 
op/op
 
 mice showed the same staining pattern as de-
scribed above (data not shown). These results demonstrate
that osteoclasts predominantly express VEGFR-1, in a man-
ner similar to monocyte/macrophage lineage cells (22, 23).
VEGF121 does not bind neuropilin-1 (21). PlGF-1 binds
VEGFR-1, but not VEGFR-2 or neuropilin-1 (21, 22–25).
The results that both rhVEGF121 and rhPlGF-1 showed ac-
tivities comparable to rhVEGF165 in the support of osteo-
clast recruitment (Table I) confirm that the response of os-
teoclast precursor cells to VEGF is mediated by VEGFR-1.
Next, we examined the capacity of VEGF and M-CSF to 
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support the survival of mature osteoclasts by neutralizing
VEGF endogenously produced in 
 
op/op
 
 mice with injections
of VEGFR-1/Fc chimeric protein. Consistent with our pre-
vious observations (12, 13), osteoclast number reached a pla-
teau at 3 d after a single rhM-CSF injection and was main-
tained up to day 7 (Tables I and II). Consecutive injections
of the chimeric protein at 12-h intervals during days 4–6
decreased osteoclasts to 
 
z
 
25%, whereas injections of human
IgG1 did not affect osteoclast number (Table II). In contrast,
when rhM-CSF was injected together with VEGFR-1/Fc,
osteoclast number increased to the levels observed in mice
consecutively injected with rhM-CSF alone. These results
indicate that survival of osteoclasts recruited after a single
rhM-CSF injection was supported by endogenously pro-
duced VEGF in 
 
op/op
 
 mice and that M-CSF can support the
survival of mature osteoclasts without the help of VEGF.
We also examined the bone resorption in the femurs of
 
op/op
 
 mice that had received either a single rhM-CSF injection
only or consecutive injections of VEGFR-1/Fc and rhM-CSF
in addition to the single rhM-CSF injection. Osteoclasts in the
former group of mice are thought to perform their functions
with the support of endogenous VEGF, whereas those in the
latter rely on exogenous rhM-CSF. As reported previously
(12), resorption of a massive amount of bone trabeculae and re-
placement with bone marrow in femurs were apparent by 7 d
after a single rhM-CSF injection (Fig. 2, A and B). Bone re-
sorption was also similarly observed in the latter group of mice
(Fig. 2 C). These observations show that both M-CSF and
VEGF can support the bone-resorbing function of osteoclasts.
The above finding that VEGF is endogenously produced
at levels sufficient for the survival of mature osteoclasts and
expression of their functions prompted us to confirm that
rhM-CSF can induce osteoclast recruitment without the
help of endogenous VEGF. As shown in Table III, twice
the number of osteoclasts were recruited by multiple injec-
tions of rhM-CSF compared with a single injection. Con-
Figure 1. Immunohistochemical staining of femur sections for VEGFRs.
Longitudinal sections of femurs of 3-wk-old 1/? mice were stained with
either anti–VEGFR-1 polyclonal antibody (A), AVAS12 anti–VEGFR-2
mAb (B), or rabbit IgG (C). Arrowheads indicate osteoclasts, and arrows
indicate endothelial cells. Original magnifications: 3238.
 
Table II.
 
Effect of Injections of VEGFR-1/Fc Chimeric Protein 
on the Survival of rhM-CSF–recruited Osteoclasts in op/op Mice
 
Treatment No. of osteoclasts/section
 
(mean 
 
6
 
 SD)
 
None 59 
 
6
 
 9
VEGFR-1Fc 15 
 
6
 
 5
Human IgG1 65 
 
6
 
 9
VEGFR-1/Fc and rhM-CSF 87 
 
6
 
 9
rhM-CSF 81 
 
6
 
 8
 
op/op
 
 mice were pretreated with a single injection of 5 
 
m
 
g rhM/CSF at
12 d of age. 5 
 
m
 
g each of VEGFR-1/Fc and/or rhM-CSF or 5 
 
m
 
g hu-
man IgG1 was consecutively injected six times at 12-h intervals into
the mice during 16–18 d of age. Osteoclasts in the longitudinal sections
of the median portion of whole femurs were counted. Results repre-
sent the mean 
 
6
 
 SD of six sections from three mice.
Figure 2. Resorption of bone trabeculae in the femurs of op/op mice by
osteoclasts with the support of endogenous VEGF or exogenous rhM-CSF.
The treatment was started at 12 d of age, and the mice were killed at 19 d of
age. Longitudinal sections of femurs were stained by Mallory’s azan. Each
micrograph represents a group of femurs from three animals. (A) No injec-
tion; (B) a single injection of 5 mg rhM-CSF at 12 d of age; (C) a single in-
jection of 5 mg rhM-CSF at 12 d of age, and six consecutive injections of
5 mg each of VEGFR-1/Fc chimeric protein and rhM-CSF at 12-h inter-
vals during 16 and 18 d of age. Original magnifications: 320.
 
Table I.
 
Capacity of rhM-CSF, rhVEGFs, and rhPlGF-1 to 
Recruit Osteoclasts in op/op Mice
 
Cytokine AFS98 No. of osteoclasts/section
 
(mean 
 
6
 
 SD)
 
None
 
2
 
3 
 
6
 
 2
rhM-CSF
 
2
 
60 
 
6
 
 6
rhM-CSF
 
1
 
14 
 
6
 
 9
rhVEGF165
 
2
 
42 
 
6
 
 1
rhVEGF165
 
1
 
43 
 
6
 
 7
rhVEGF121
 
2
 
37 
 
6
 
 4
rhPlGF-1
 
2
 
37 
 
6
 
 2
rhPlGF-1
 
1 35 6 2
Cytokines were injected at a single dosage of 5 mg into 12-d-old op/op
mice, and mice were killed 3 d after the injection. AFS98 anti–c-Fms
mAb was injected at a dosage of 750 mg/mouse both 2 h before and 24 h
after the cytokine injection. Osteoclasts in the longitudinal sections of
the median portion of whole femurs were counted. Results represent
the mean 6 SD of six sections from three mice.296 Vascular Endothelial Growth Factor Supports Osteoclastic Bone Resorption
comitant injections of VEGFR-1/Fc with rhM-CSF did
not affect osteoclast recruitment. These results are the first
unequivocal demonstration of the capacity of M-CSF to
support in vivo osteoclast differentiation.
It became clear that M-CSF supports osteoclast differen-
tiation in cooperation with osteoclast differentiation factor
(ODF)/osteoprotegerin ligand (OPGL)/TNF-related acti-
vation-induced cytokine (TRANCE)/RANKL (31, 32). We
examined whether rhVEGF165 can replace rhM-CSF in os-
teoclast generation in in vitro culture of nonadherent bone
marrow cells. Consistent with previous observations (31, 32),
no TRAP-positive cells appeared in the presence of rhM-
CSF or rhRANKL alone (data not shown). rhVEGF165
alone also failed to support the osteoclast differentiation (Fig.
3 A). A combination of rhVEGF165 and rhRANKL sup-
ported the generation of TRAP-positive cells (Fig. 3 B), al-
though the cells were significantly smaller in size than those
generated in the presence of rhM-CSF and rhRANKL (Fig.
3 C). Consequently, the osteoclasts supported by rhVEGF165
and rhRANKL formed smaller resorption lacunae than those
supported by rhM-CSF and rhRANKL (Fig. 3, D and E).
These results demonstrate that VEGF can indeed support
osteoclast differentiation in cooperation with ODF/OPGL/
TRANCE/RANKL.
Finally, we examined whether progressive correction of
osteopetrosis with age accompanied by an increase of osteo-
clasts in op/op mice (1, 2, 11) is due to endogenously pro-
duced VEGF. As shown in Fig. 4 A, a significantly larger
number of small osteoclasts with 2–3 nuclei was observed in
the femurs of 2-mo-old op/op mice (28 6 1 osteoclasts/sec-
tion) compared with those of 2-wk-old mutants (Tables I and
III), even though the size of the femur sections of the older
animals was z1.6 times larger than that of younger ones. In
addition, TRAP-positive mononuclear cells were frequently
observed in the marrow space. Five consecutive injections of
100 mg goat anti-VEGF polyclonal antibody at 12-h intervals
Figure 4. Dependence of osteoclasts in the femurs of 2-mo-old op/op
mice on endogenously produced VEGF. The mice were killed 3 d after the
onset of the treatment. Longitudinal sections of femurs were stained for
TRAP activity and counterstained with hematoxylin. Each micrograph
represents a group of femurs from three animals. Arrows in B indicate
mononuclear TRAP-positive cells. (A) No injection; (B) five consecutive
injections of 100 mg anti-VEGF polyclonal antibody at 12-h intervals; (C) a
single injection of 5 mg rhVEGF165. Original magnifications: 3103.
Figure 3. Ability of VEGF to support in vitro generation of osteoclasts.
Nonadherent bone marrow cells were cultured in the presence of
rhVEGF165 alone (A), rhVEGF165 and rhRANKL (B and D), or
rhM-CSF and rhRANKL (C and E) in the wells of 96-well plates (A–C)
or on dentine slices (D and E) for 7 d. The cultures were either stained for
TRAP activity (A–C) or examined by backscattered electron microscopy
(D and E). Arrows in D indicate small resorption lacunae. Original mag-
nifications (A–C): 325. Bars (D and E): 50 mm.
Table III. Effect of VEGFR-1/Fc Injection on Osteoclast 
Recruitment by rhM-CSF in op/op Mice
Treatment
No. of 
injections
No. of 
osteoclasts/section
(mean 6 SD)
None 0 3 6 2
rhM-CSF 1 56 6 9
rhM-CSF 6 108 6 11
rhM-CSF and VEGFR-1/Fc 6 101 6 7
The treatments of op/op mice began at 12 d of age. They received either a
single injection of 5 mg rhM-CSF or six consecutive injections of 5 mg
rhM-CSF alone or together with 5 mg VEGFR-1/Fc at 12-h intervals, and
were killed at 3 d after the onset of the treatments. Osteoclasts in the longi-
tudinal sections of the median portion of whole femurs were counted. Re-
sults represent the mean 6 SD of six sections from three mice.297 Niida et al. Brief Definitive Report
significantly decreased osteoclast number (4 6 2 osteoclasts/
section; Fig. 4 B). Injections of goat IgG did not affect osteo-
clast number (data not shown). VEGFR-1/Fc injections ac-
cording to the protocol applied to 2-wk-old mutant mice
(Table II) failed to show any noticeable effect on osteoclast
number (data not shown). A single injection of 5 mg
rhVEGF165 induced further recruitment of osteoclasts (64 6
5 osteoclasts/section; Fig. 4 C), indicating that VEGF levels
in the femurs of 2-mo-old op/op mice are still insufficient
to recruit osteoclasts at maximum level. These results demon-
strate that VEGF is responsible for the spontaneous osteoclast
recruitment in the absence of functional M-CSF in op/op
mice. Changes in osteoclast number with the age and differ-
ence in the amount of VEGFR-1/Fc required to neutralize
endogenous VEGF activity in 2-wk- and 2-mo-old animals
suggest higher levels of VEGF production in older mutant
mice, although the possibility that sensitivity of osteoclast pre-
cursors to VEGF changes with age cannot be ruled out.
This study demonstrates that M-CSF and VEGF can play
almost entirely overlapping roles in osteoclastic bone re-
sorption. The presence of either of the cytokines was suffi-
cient to support all the processes of osteoclastic bone re-
sorption,  i.e., the differentiation of osteoclasts and their
survival and active bone resorption, representing a unique
type of redundancy of cytokine signaling. However, osteo-
clasts generated in vitro with the support of rhVEGF165
and rhRANKL were significantly smaller in size and formed
smaller resorption lacunae compared with those supported
by rhM-CSF and rhRANKL. Osteoclasts observed in 2-mo-
old op/op mice had only two to three nuclei. Nevertheless,
our data indicated that progressive correction of osteopetrosis
in op/op mice is due to endogenously produced VEGF.
It has been well established that VEGF is a key regulator
of vasculogenesis (21). Osteoclastic bone resorption and con-
comitant bone marrow formation are closely associated with
active neovascularization (8, 33), and osteoblasts have been
reported to produce VEGF (34). Our results indicate that
VEGF is produced in op/op mice at levels sufficient for the
survival and functioning of mature osteoclasts, but not for
their recruitment at maximal levels. The finding that mice
lacking a single VEGF allele die in utero with aberrant blood
vessel formation in the yolk sac and embryo indicates that
VEGF is produced at threshold levels for endothelial cell
proliferation (35, 36). Furthermore, mice expressing the
VEGFR-1 lacking the tyrosine kinase domain (26) had no
appreciable abnormality in osteoclastic bone resorption (M.
Shibuya, The University of Tokyo, personal communication).
Therefore, M-CSF seems to play a dominant role in osteo-
clastic bone resorption under physiological conditions.
Macrophages from mice with kinase-deficient VEGFR-1
exhibit a defect in their migratory response to VEGF (26). The
common feature of predominant expression of VEGFR-1 in
monocytes and macrophages (21–23) and in osteoclasts may
provide further support for the view of shared origin of these
cells. We found previously that multiple injections of rhM-
CSF are required for macrophage recruitment in the femurs of
op/op mice (12, 13). In the present study, we also failed to find
any sign of macrophage recruitment in the femurs after a single
injection of rhVEGFs or rhPlGF-1 (data not shown). These ob-
servations may suggest that macrophage lineage cells are less sen-
sitive to M-CSF, VEGFs, and PlGF-1 compared with osteoclast
precursors or more probably that macrophage precursors are
more strictly dependent on the continuous presence of M-CSF.
The function of VEGFR-1 as a mediator of mitogenic
response of endothelial cells to VEGF has yet to be clearly
identified, although unequivocal evidence for such a role
of VEGFR-2 has accumulated (21). The phenotypes of the
mice with VEGFR-1 deficiency (37) and those expressing
kinase-deficient VEGFR-1 (29) strongly suggest the role of
VEGFR-1 in the negative regulation of endothelial growth
in embryonic angiogenesis. Therefore, it is of interest to
compare the VEGFR-1 signaling in osteoclasts and their
precursor cells with that in endothelial cells.
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